Background: Congenital hyperinsulinism (CHI) is frequently caused by mutations in one of the K ATP channel subunits encoded by the genes ABCC8 and KCNJ11. The effect of simultaneous mutations in both of these genes on the pancreatic β-cell function is not known and patients with CHI carrying both ABCC8 and KCNJ11 mutations have not yet been reported. We questioned if a combination of heterozygous mutations in the ABCC8 and KCNJ11 genes could also lead to β-cell dysfunction presenting as CHI. Methods: As a model, we used a patient with transient CHI that paternally inherited novel heterozygous mutations in ABCC8 (p.Tyr1293Asp) and KCNJ11 (p.Arg50Trp) genes. The pathogenic effects on the pancreatic β-cells function were examined in an in vitro functional study using radioactive rubidium efflux assay. Results: We showed that the activation of the mutated K ATP channels by diazoxide was decreased by 60.9% in the channels with the heterozygous combination of both mutations compared to the wild type channels. This could indicate the pathogenic effect on the pancreatic β-cell
Introduction
Congenital hyperinsulinism (CHI) is a common cause of persistent neonatal hypoglycemia. CHI is caused by mutations in the genes that are crucial for the regulation of insulin secretion from pancreatic β-cells [1] . In particular, mutations in sulfonylurea receptor 1 (SUR1), one of the adenosine triphosphate-sensitive K + channel (K ATP ) subunits, and the pore-forming subunit (K ir 6.2), which are encoded by the genes ABCC8 and KCNJ11 [2] , respectively, are responsible for the development of CHI. A wide spectrum of mutations in these genes has been described, ranging from severe homozygous and compound heterozygous to milder heterozygous variants [3] [4] [5] . The majority of CHI cases caused by mutations in the ABCC8 or KCNJ11 genes require intensive treatment during the first years of life. A part of the most severe cases of diffuse CHI caused by homozygous mutations in the respective genes that previously had to be treated with near-total pancreatectomy, can now be successfully managed with sirolimus [6] . In contrast, focal lesions (paternally inherited heterozygous mutations) can be localized by 18 F 3,4-dihydroxyphenylalanine positron emission tomography/computer tomography and surgically removed. Alternatively, some of these children can be successfully treated with octreotide. Generally, patients with CHI show gradual improvement of their condition over time allowing for less intensive treatment. However, spontaneous remission within the first 3 years of life is not common [3, 7] .
Identification of one patient with CHI carrying heterozygous variants in the ABCC8 and KCNJ11 genes simultaneously led us to question if a combination of two mutations in different genes alter the pancreatic β-cell function.
Subjects and methods

Patient -clinical information
The male infant was the second child born to non-consanguineous, healthy Caucasian Czech parents with no family history of hypoglycemia or diabetes. He was born at the 36th week of gestation by normal delivery with an Apgar score of 9-8-8. He was large for his gestational age with a birth weight of 4.0 kg (+2.76 standard deviation score [SDS] ) and a length of 51 cm (+1.31 SDS). Gestational diabetes in the mother was excluded by an oral glucose tolerance test (oGTT) in the 24th week of gestation. After birth, the patient was diagnosed with transposition of the great arteries and underwent cardiothoracic surgery at the age of 7 days. Since the first day of life, he presented with persistent non-ketotic hypoglycemia and unsuppressed insulin levels (blood glucose 1.3 mmol/L, β-hydroxybutyrate 0.2 mmol/L, insulin 29.9 mIU/L, C-peptide 1 811.0 pmol/L, cortisol 441 nmol/L). The patient was managed with parenteral administration of dextrose (above 10 mg/kg/min) and fortification of oral feeding with maltodextrin. On the 6th day of life, treatment with s.c. octreotide (5 μg/kg/day) instead of diazoxide was initiated because it was not clear when and how the patient would be able to tolerate oral medication due to cardiothoracic surgery. The dose was gradually increased with a simultaneous reduction in the parenteral administration of dextrose so that it could be stopped once the dose of octreotide reached 25 μg/kg/day on the 14th day of life. Because of the occasionally low blood glucose levels, the octreotide dose was subsequently increased to 35 μg/kg/ day. On the 19th day of life, therapy with diazoxide (9.1 mg/kg/day) together with thiazide diuretics was introduced, maintaining blood glucose levels within the normal range and allowing for the reduction of the octreotide dose until it could be stopped. The patient's blood glucose levels were stable on the diazoxide therapy. However, since the fourth week of life, the patient was noted to be exhausted with feeding and tachycardic. Despite the intensified therapy with diuretics in the fifth week of life, he presented with episodes of desaturation, lethargy and hypotonia. Echocardiography revealed dilated cardiomyopathy affecting both atria and leading to mitral and tricuspid insufficiency. His levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) were significantly elevated (16,248 ng/L, normal range 37-646 ng/L) in accordance with the echocardiographic findings. Due to a suspicion of diazoxide cardiotoxicity, the treatment with diazoxide was stopped, and octreotide was re-introduced.
Within several days after stopping the diazoxide treatment, the clinical state of the patient improved, the episodes of desaturation and tachycardia resolved, the echocardiographic findings normalized and the NT-proBNP levels decreased (4388 ng/L). The patient was discharged at the age of 7 weeks on monotherapy with octreotide (35 μg/kg/day), which were tolerated well. At the age of 7 months, the therapy was switched to a more convenient therapy with a long-acting octreotide analog (Sandostatin-LAR) administered i.m. (5 mg) once every 4 weeks. The dose of short-acting octreotide was gradually decreased and eventually stopped 2 months thereafter. To our knowledge, a Sandostatin-LAR has not been used in children with CHI previously. The recommended single dose for an adult is 30 mg. We therefore opted for 4 mg i.m. every 4 weeks for an infant, which proved to be sufficient as the patient's glycemic control was satisfactory until the age of 2.5 years when the treatment could be stopped with no further episodes of hypoglycemia (able to fast for 11 h, home blood glucose levels between 3.6 and 9.1 mmol/L) and a satisfactory growth trajectory (weight −0.28 SDS, height −1.38 SDS). The patient's psychomotor development was normal.
Genetic testing
The patient's genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The patient was tested for the genes associated with CHI, as published previously [8] . We tested the complete coding region and the intron-exon boundaries of the ABCC8 (GenBank accession number NG_008867), KCNJ11 (GenBank accession number NG_012446), GCK, HNF4A, HNF1A, GLUD1, HADH, UCP2 and SLC16A1 genes by Sanger sequencing. We also analyzed the ABCC8 gene using multiplex ligation-dependent probe amplification (MRC-Holland, Amsterdam, Netherlands) in order to rule out possible deletions or duplications. To assess the origin of the mutations, sequencing of relevant exons was also carried out in DNA samples from the patient's parents. All primer sequences and protocols are available upon request.
Written informed consent was obtained from the parents of the patient. The protocol of the study was approved by the Institutional Ethics Committee of the 2nd Faculty of Medicine, Charles University in Prague, the Czech Republic and fulfills the Declaration of Helsinki regarding ethical conduct of research involving human subjects.
Functional study
To determine the pathogenicity of the novel mutations in the K ATP channel subunits, we performed an in vitro functional analysis as described previously [8, 9] . Plasmid vectors expressing the mutant SUR1 and K ir 6.2 subunits were created by Quick Change Site Directed Mutagenesis Kit (Stratagene, San Diego, USA), the ABCC8 and KCNJ11 gene mutation specific primers used are available upon request. Vectors cDNA3 (Invitrogen, Carlsbad, USA) for SUR1 (accession number L40623) and pcDNA3.1/Zeo (accession number D50581) (Invitrogen) for K ir 6.2 were used in this study. A highly conserved and previously exploited [10] cDNA sequences of hamster (ABCC8 cDNA) and mouse (KCNJ11 cDNA) were used as templates. Both of them have 95% sequence homology to the respective human proteins. The online Clustal program was used to align these sequences with the human cDNA in order to locate the mutations found in our patient.
To assess the pathogenicity of the novel variants in genes ABCC8 and KCNJ11, an analysis using radioactive rubidium (Rb 86+ ) efflux assay was performed in human embryonic kidney 293 (HEK293) cell cultures that were transfected with combinations of the mutations in both the K APT channel subunits.
The mutant and wild type (WT) channels were exposed to five different drug conditions: (1) control -dimethyl sulfoxide (DMSO), (2) 100 μM diazoxide, (3) 100 μM diazoxide and 10 μM glibenclamide, (4) metabolic inhibition (MI) using 2.5 mM NaCN and 20 mM 2-deoxy-D-glucose, and (5) MI and 10 μM glibenclamide. For more details on the experimental conditions see the Figure 2 legend.
To better understand the effects of the novel mutations on the β-cell function, we first tested the mutations separately in the homozygous and heterozygous states. Then we tested combinations of these mutations in homozygous and heterozygous state, which reflected the situation in our patient.
Results
Genetic testing
The genetic analyses revealed a unique combination of novel heterozygous mutations in both of the K ATP channel subunits, namely the novel p.Tyr1293Asp (c.3877T>G) mutation in the ABCC8 gene and the novel p.Arg50Trp (c.148C>T) mutation in the KCNJ11 gene. No mutations were identified in the other common genes associated with CHI that were tested. Both of the identified mutations were not listed in the 1000 Genomes Project, however, the p.Tyr1293Asp in the heterozygous state was reported in four subjects in the ExAc database. On the other hand, none of the reported mutations were detected in 100 chromosomes of healthy control subjects of Czech ancestry, and both were described as pathogenic by the in-silico prediction programs SIFT and PolyPhen-2. Paternal inheritance was observed. However, the father did not have any documented episodes of hypoglycemia in infancy, and his actual glycemic response at the age of 35 years was normal (normal oGTT and a glycated hemoglobin of 32 mmol/mol and 5.1%, respectively). He was significantly macrosomic at birth with a weight of 4.75 kg (+3.15 SDS), which may reflect a defect in insulin secretion in utero and supports the suggested dominant mode of action of the mutations ( Figure 1 ) and a probable mild, transient hyperinsulinism in infancy. Because the paternal mode of inheritance was suggestive of a focal form of CHI, a 18 F 3,4-dihydroxyphenylalanine positron emission tomography/computer tomography scan was performed, but no focal lesions were detected.
Functional study
The β-cell function was assessed as K ATP channel activity when exposed to diazoxide. Both novel mutations significantly decreased the activity of the K ATP channel in comparison to WT channels when expressed separately in a homozygous state -by 84.3% for mutation p.Tyr1293Asp in gene ABCC8 and by 75% for mutation p.Arg50Trp in the gene KCNJ11 (see Figure 2) . On the other hand, when expressed separately in a heterozygous state the effect on the K ATP channel activity was smaller (38.5% and 45.4%, respectively, see Figure 2) .
The most deteriorating effect on the β-cell function represented by K ATP channel activation by diazoxide was observed when a combination of the homozygous mutations was expressed simultaneously -channel activity decreased by 86.3% (Figure 2) .
The functional study of the unique combination of heterozygous mutations, which accurately mimics the situation in our patient, revealed that the activation of mutated K ATP channels by diazoxide was decreased by 60.9% when compared to WT channels (Figure 2) .
To assess the activation of endogenous pathways via MI, additional control experiments including un-transfected cells (UTF) and cells transfected with K ir 6.2 only were performed. The WT K ATP channels had the strongest response to MI with an Rb 86+ efflux of 65.5% ± 15.5% after a 15-min incubation, and there was a response to MI in some of the mutants.
Discussion
The p.Arg50Trp mutation in the KCNJ11 gene acts as a dominant mutation. It was non-functional when expressed in a homozygous state, but its activity improved in the presence of WT subunits. The arginine residue at position 50 may play an indirect role in the process of ATP binding, as well as affecting ATP sensitivity within the K ir 6.2 protein [11, 12] . Therefore, we hypothesize that the ATP sensitivity was enhanced, which explains why the channel remained closed even in the presence of diazoxide.
The p.Tyr1293Asp mutation in the ABCC8 gene is located within transmembrane domain 2 of the SUR1 protein. This channel was activated by MI even when expressed in the homozygous state. It is likely that the MgADP-binding site was still intact, which was why the channel was responsive. However, the diazoxide-binding site had clearly been damaged.
A combination of the mutations and the WT subunits showed that functional K ATP channels remained, which were responsive to channel activators. This explains why the patient was responsive to medical treatment. Moreover, the mild effect of these mutations explains the tendency for spontaneous remission of CHI.
The results of this functional study could indicate that the presence of single heterozygous mutations alters the K ATP channel slightly, and the combination of these mutations intensifies their pathogenic effects. However, against this hypothesis are presence (albeit in single cases) of the ABCC8 variant p.Tyr1293Asp in databases of polymorphisms, inconsistent phenotype of the proband and his father and maintained activation of the channel by MI in the experiment. Moreover, due to financial and technical reasons we were not able to perform surface expression assays that could assess the protein expression of the mutant constructs in HEK293 cells. Therefore, further investigation using additional functional methods and/or additional detection of patients carrying combination of variants in the genes encoding K ATP channel subunits would be needed to confirm this newly described phenomenon.
From the clinical point of view it is important to note that the mild phenotype could be missed during the neonatal and infant periods. This could explain that the same combination of mutations was detected in the patient's healthy father, who was born large for his gestational age, but had no documented episodes of hypoglycemia. Alternatively, as the phenotypical variabilities in identical mutations detected even in members from same families are very common, it is definitely possible that the functional characteristics of a mutation evaluated in vitro could be different from the in vivo effects.
In conclusion, we have reported for the first time a case involving a patient with transient CHI that might be caused by a combination of novel heterozygous mutations in the genes encoding the K ATP channel subunits. Although our results indicate a pathogenic effect of this combination of mutations on pancreatic β-cell function through an in vitro functional study, further investigation is needed to confirm it. Our findings will then widen the spectrum of genetic causes of CHI and suggested a novel pathogenic mechanism of CHI.
